Evaluation of FLT3L Armoured CAR T-cells in HER2 Expressing Malignant Diseases in Adults
Key facts
- Who runs it
- Peter MacCallum Cancer Centre, Australia
- Where
- Australia1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 1
- People taking part
- 12 people, planned
- Starts
- 21 Nov 2026
- Expected to end
- 1 Oct 2029
- Type of study
- Interventional
- Treatments tested
- PMCC-COE-HER2FLT3L
- Record updated
- 16 November 2026
Who can take part
- Age
- 16 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 34 criteriaShow less
Who can take part
- Patient (and/or their legal guardian) has provided written informed consent using the ECHIDNA Patient Information and Consent Form (PICF)
- Age ≥ 16 years on the day of signing informed consent
- Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 to 2 (Appendix 6)
- Patients should have unresectable, or metastatic disease based on most recent imaging. The following tumour types are eligible for this study:; Patients with histologically documented HER2-positive breast cancer: Tumour must be HER2 in situ hybridisation (ISH)-positive by local testing using current American Society of Clinical Oncology-College of American Pathologists (ASCO-CAP) guidelines for scoring in breast cancer. Patients must have progressed after and/or are not suitable for a trastuzumab-containing treatment and trastuzumab deruxtecan per investigator assessment; Patients with histologically documented gastric/gastroesophageal junction cancer: Tumour must be HER2 IHC 3+ or IHC 2 +/ISH-positive based on local tissue testing results in accordance with ASCO-CAP guidelines for scoring in gastroesophageal adenocarcinoma. Patients must have progressed after at least one prior trastuzumab-containing regimen; Patients with histologically documented colorectal cancer: Tumour must be HER2 IHC 3+ or IHC 2+/ISH-positive based on local tissue testing results in accordance with ASCO-CAP guidelines for scoring in gastroesophageal adenocarcinoma. Patients must have progressed after available therapies including fluoropyrimidine based chemotherapy; Other tumour types: Patients with histologically confirmed biliary tract cancer (including intra- or extrahepatic cholangiocarcinoma and tumours arising in the ampulla of Vater or gallbladder), cervical cancer, endometrial cancer, sarcoma, salivary duct carcinoma, and pancreatic adenocarcinoma. Tumour must be HER2 IHC 3+ or IHC 2+/ISH-positive based on local tissue testing results in accordance with ASCO-CAP guidelines for scoring in gastroesophageal adenocarcinoma. Patients must have progressed following at least one prior systemic treatment and have no satisfactory alternative treatment option as judged by the investigator; Note: Patients who have had prior treatment with a HER2-targeting CAR T-cell therapies will be potentially eligible, if detectable HER2 expression on malignant cells can be demonstrated (per eligibility criterion #4) and at least 3 months has elapsed between the infusion of any prior cellular therapies and the infusion of the PMCC-COE-HER2FLT3L. If a prior HER2-targeting CAR T-cell therapy has been previously infused, baseline CAR T-cell quantification will be performed on peripheral blood prior to the infusion of PMCC-COE-HER2FLT3L, as outlined in the Schedule of Assessments at the Pre-Leukapheresis timepoint, Section 9.2.1)
- Have measurable disease, as defined by RECIST1.1 (Appendix 1)
- Have a life expectancy of ≥ 3 months, as judged by the investigator
- Adequate haematological function documented within 7 days prior to registration, defined as:; Haemoglobin ≥ 80 g/L (peripheral red blood cell transfusion support is allowed); Absolute neutrophil count (ANC) ≥ 1.0 x 109/L (granulocyte-colony stimulating factor [G-CSF] support is allowed, and ANC > 0.5 x 109/L is allowed if neutropenia is due to disease infiltration of bone marrow); Absolute lymphocyte count (ALC) ≥ 0.1 x 109/L; Platelets ≥ 50 x 109/L
- Adequate cardiac function, defined as:; Left ventricular ejection fraction (LVEF) ≥ 50% on echocardiogram (ECHO) or multigated acquisition (MUGA) scan within 90 days prior to registration; No suspicion for intercurrent deterioration in left ventricular function as assessed by the investigator
- Adequate pulmonary function, defined as:; Oxygen saturation measured by pulse oximetry ≥ 90% on room air
- Adequate renal function documented within 7 days prior to registration, defined as any one of:; A serum creatinine ≤ 1.5 x upper limit of normal (ULN); Creatinine clearance (CrCl) of ≥ 40 mL/min calculated by Cockcroft-Gault formula (Appendix 7); CrCl ≥ 40 mL/min calculated by 24-hour urine collection; Glomerular filtration rate (GFR) ≥ 40 mL/min by renal scintigraphy
- Adequate hepatic function documented within 7 days prior to registration, defined as all of:; Total bilirubin ≤ 1.5 x ULN (or ≤ 3.0 x ULN in patients with Gilbert's syndrome or documented liver involvement); Alanine aminotransferase (ALT) ≤ 3.0 x ULN (or ≤ 5.0 x ULN in patients with documented liver involvement); Aspartate aminotransferase (AST) ≤ 3.0 x ULN (or ≤ 5.0 x ULN in patients with documented liver involvement)
- Taking a maximum corticosteroid dose of 20 mg of oral prednisolone or equivalent
- Females of childbearing potential (FCBP) and non-sterile male patients (with partners of childbearing potential) must agree to use highly effective methods of contraception from registration on the study to 2 months after the PMCC-COE-HER2FLT3L infusion or until PMCC-COE-HER2FLT3L is no longer present by quantitative PCR on two consecutive tests whichever is later. Effective methods of contraception are:; Total abstinence from sexual intercourse when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception; Female sterilisation (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or bilateral tubal ligation at least 6 weeks prior to registration. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessment; Male sterilisation (at least 6 months prior to screening), noting that for female patients on the study, the vasectomised male partner should be the sole partner for that patient; Use of oral, (oestrogen and progesterone), injected or implanted hormonal methods of contraception or placement of an intrauterine device or intrauterine system, or other forms of hormonal contraception that have comparable efficacy (failure rate < 1%), for example hormone vaginal ring or transdermal hormone contraception. In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months prior to registration; Women are considered post-menopausal and not of child-bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g., age-appropriate history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or tubal ligation at least 6 weeks prior to registration. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessment is she considered not of childbearing potential
- Females of childbearing potential must have a negative serum beta-human chorionic gonadotropin (β-hCG) pregnancy test within 3 days prior to registration
- Sexually active male patients must use a condom during intercourse and must agree to refrain from sperm donation, from registration on the study until 12 months after PMCC-COE-HER2FLT3L infusion
Who cannot take part
- Active interstitial lung disease (ILD)/pneumonitis or history of (non-infectious) ILD/pneumonitis within 60 days prior to registration
- Symptomatic, or active central nervous system (CNS) metastases and/or carcinomatous meningitis; Note 1: Patients with previously treated brain metastases may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging, clinically stable, and without requirement of steroid treatment for at least 14 days prior to registration. Anticonvulsant therapy at a stable dose is permitted; Note 2: Patients with untreated brain metastases not requiring immediate local therapy are eligible provided all CNS lesions are < 2.0 cm in maximal diameter on contrast brain MRI, they are clinically stable, and without requirement of steroid treatment for at least 14 days prior to registration. Anticonvulsant therapy at a stable dose is permitted; Note 3: Patients with metastases to the midbrain, pons, medulla, or spinal cord are not eligible
- Major surgery within 4 weeks prior to registration
- Receipt of a live, attenuated vaccine (except for COVID-19) within 4 weeks prior the planned commencement of lymphodepleting conditioning
- Receipt of any investigational medical product within the last 30 days, or after 5 half-lives (whichever is the shortest) prior to planned leukapheresis
- Active HIV or hepatitis A, B, or C infection; Patients who are positive for HIV by enzyme-linked immunosorbent assay or Western Blot, are ineligible; Patients who are seropositive for hepatitis C virus (HCV) are eligible if their most recent HCV DNA assay is undetectable (including those that have received curative therapy); Patients who are seropositive for hepatitis B virus (HBV) due to prior infection may be eligible, if their most recent HBV DNA assay is undetectable, and suitable prophylactic therapy is given prior to and after treatment with PMCC-COE-HER2FLT3L (e.g., entecavir); Patients who are seropositive for HBV because of vaccination (surface antibody positivity only) are eligible
- Patients with CNS disease who cannot undergo MRI assessment
- Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure or myocardial infarction within 6 months of screening or class III to IV cardiac disease as defined by the New York Heart Association Functional Classification
- Clinically significant neurological disorders (e.g., epilepsy, severe brain injury, dementia, Parkinson's disease, or autoimmune/inflammatory disorders [e.g., Guillain-Barre syndrome, motor neuron disease, chronic inflammatory demyelinating polyneuropathy])
- History of other active malignancy, with the exception of:; Adequately treated in situ carcinoma of the cervix or breast; Adequately treated basal cell carcinoma of skin or localised squamous cell carcinoma of the skin; Low grade malignancies that are being observed and do not require treatment (e.g., low risk prostate cancer); Previous malignancy confined and surgically resected (or treated with other modalities) with curative intent and without evidence of recurrence for at least 2 years prior to registration
- A known history or current autoimmune disease or other diseases resulting in permanent immunosuppression or requiring permanent immunosuppressive therapy (with the exception of corticosteroids up to 20 mg/day of oral prednisolone or equivalent)
- Current active graft versus host disease (GVHD) requiring immunosuppression (with the exception of corticosteroids up to 20 mg/day of oral prednisolone or equivalent)
- Known hypersensitivity to the excipients of PMCC-COE-HER2FLT3L or to any product to be given to the patient as per the study protocol (e.g., tocilizumab and lymphodepleting agents)
- Presence of any psychological, social, geographical, or other condition for which, in the opinion of the investigator, participation would not be in the best interest of the patient (e.g., compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments
- Other clinically significant active infection confirmed by clinical evidence, imaging, or positive laboratory tests (e.g., blood cultures, viral DNA/RNA by PCR)
- Other significant life-threatening illness, medical condition, or laboratory abnormality that, in the opinion of the investigator, could compromise the patient's safety, impair their ability to receive PMCC-COE-HER2FLT3L, or put the study outcomes at undue risk
- Uncontrolled pleural effusion(s), ascites or pericardial effusion that requires repeated drainage procedures
- Patients with brain stem lesions
- Women who are lactating
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to learn if a novel CAR-T cell therapy, called autologous PMCC-COE-HER2FLT3L CAR-T cells, is safe and effective at treating solid tumours that express high levels of the marker HER-2. Patients who have solid tumours that express the marker HER-2, and who have previously progressed or where unsuitable for current HER-2 targeted medications, will be recruited to the study. The PMCC-COE-HER2FLT3L CAR T-cells will be produced using LV and administered to patients after lymphodepleting conditioning chemotherapy. Patients will be then monitored for any side effects as a result of the CAR-T infusion and will have scans performed to assess how their tumour responds to the therapy.
The group in the trial
- PMCC-COE-HER2FLT3LTreatment being tested
Single dose of PMCC-COE-HER2FLT3L CAR-T cells administered following lymphodepleting chemotherapy
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Evaluation of FLT3L Armoured CAR T-cells in HER2 expressIng Malignant Diseases iN Adults
- Record updated
- 16 November 2026